Condensed Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:
Biocatalyst product sales	$ 2,562	$ 1,076	$ 8,323	$ 15,161
Biocatalyst research and development	3,364	2,028	7,176	4,936
Revenue sharing arrangement	1,546	839	5,617	2,300
Total revenue	7,472	3,943	21,116	22,397
Costs and operating expenses:
Cost of biocatalyst product sales	1,532	494	6,179	9,790
Research and development	5,038	6,831	17,708	22,776
Selling, general and administrative	5,157	5,832	16,791	21,126
Total costs and operating expenses	11,727	13,157	40,678	53,692
Loss from operations	(4,255)	(9,214)	(19,562)	(31,295)
Interest income	3	9	15	53
Other expenses	(57)	(22)	(183)	(288)
Loss before income taxes	(4,309)	(9,227)	(19,730)	(31,530)
Provision for (benefit from) income taxes	253	35	(314)	(41)
Net loss	$ (4,562)	$ (9,262)	$ (19,416)	$ (31,489)
Net loss per share, basic and diluted (dollars per share)	$ (0.12)	$ (0.24)	$ (0.51)	$ (0.83)
Weighted average common shares used in computing net loss per share, basic and diluted (shares)	38,450	38,102	38,063	38,002